Adaltis

Adaltis is a commercial-stage, privately-held Italian IVD company with a 25+ year history. It has built a diversified portfolio spanning molecular diagnostics instruments and test kits, automated MicroELISA analyzers, and associated reagents. The company leverages both open-platform instruments and proprietary test panels, serving a global market through a direct and partner sales model. Its recent focus includes expanding its syndromic molecular panels and fully integrated 'All-in-One' MDx platforms to capitalize on the growing demand for automated, high-throughput infectious disease testing.

Dual-platform diagnostics: 1) Molecular Diagnostics (MDx) with automated nucleic acid extraction (EXTRAlab, eLAB), real-time PCR (AMPLilab), fully integrated 'All-in-One' systems (MDXlab), and syndromic multiplex PCR test panels (MOLgen). 2) Immunoassay/MicroELISA with automated analyzers (Personal LAB, NEXgen) and associated reagent kits, including in-house conjugate and TMB substrate production.

Adaltis competes in a fragmented but top-heavy global IVD market. In molecular diagnostics, it competes with giants like Roche, Abbott, BioMérieux, and Qiagen, as well as specialized firms like Seegene and Diasorin. In automated ELISA, competitors include Thermo Fisher, DiaSorin, and PerkinElmer. Its strategy focuses on specific syndromic panels, open systems, and integrated automation to differentiate.